Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results (Q34679340)

3 August 2017

1 reference

title

Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results (English)

1 reference

non-small-cell lung carcinoma

3 August 2017

1 reference

1 reference

3

Roy S Herbst

1 reference

3 August 2017

Ralph G Zinner

1

1 reference

PubMed ID

12057863

3 August 2017

Jeri Kim

series ordinal

2

1 reference

3 August 2017

1 July 2002

1 reference

3 August 2017

1 reference

3 August 2017

37

1 reference

3 August 2017

17-27

1 reference

3 August 2017

1

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The neu oncogene encodes an epidermal growth factor receptor-related protein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Effect of HER2/neu expression on survival in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Signal transduction by receptors with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Signal transduction: multiple pathways, multiple options for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Dimerization of cell surface receptors in signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Analysis of serum ErbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

C-erbB-2 protein in the sera of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

The neu-oncogene product in serum and tissue of patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

Monitoring therapy by serum HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900035-1

7 January 2021

10.1016/S0169-5002(02)00035-1

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12057863